Home

vendeur Camion lourd corde novartis zolgensma press release Volcanique Marguerite jambe

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonge

$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian

Test Achats porte plainte contre un médicament à 2 millions d'euros
Test Achats porte plainte contre un médicament à 2 millions d'euros

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Path clears for Novartis's Zolgensma after FDA lifts longstanding hold
Path clears for Novartis's Zolgensma after FDA lifts longstanding hold

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times
Novartis says it knew of Zolgensma data problems before U.S. approval - The Japan Times

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR

Zolgensma gene therapy for sma patients: long-term data
Zolgensma gene therapy for sma patients: long-term data

Novartis Media Release guide - August 2019
Novartis Media Release guide - August 2019

Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology

Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest

EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA
Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing - Cure SMA

News Archive | Novartis
News Archive | Novartis

Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma

Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace
Novartis Reveals Two Deaths Related to SMA Drug Zolgensma | BioSpace

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace
FDA Lifts Partial Clinical Hold on Novartis' Gene Therapy Trial for Spinal Muscular Atrophy | BioSpace

Novartis faces serious delays in registration of Zolgensma in Russia
Novartis faces serious delays in registration of Zolgensma in Russia

FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association
FDA Accepts AveXis' BLA for SMA Drug Zolgensma Under Priority Review - Muscular Dystrophy Association

Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance